National Authorities’ interpretation of orphan drugs legislation and its impact on drug development
How to improve processes for designation and speed up approval processes
Relevance of Patient Registries in the development of clinical research
How to effectively prepare for commercialization within Europe, the US and beyond
The essential role of patient organisations in promoting access to treatment
How to maximize partnerships and alliances
Who should Attend
CMOs, CEOs and CSOs from biotech companies
Presidents, CEOs, Directors, VPs and Heads/Managers from Pharmaceutical Companies involved in Therapeutic Development, Orphan Drug Discovery/Development, Business Unit, Marketing & Medical Affairs, External Affairs, Regulatory Affairs and Market Access
HTA agencies
Regulatory Bodies
Research centres
Academics
Past Events
3rd Annual Orphan Drugs Congress 2014 - 21-22 May 2014, Hotel Silken Diagonal Barcelona, Spain (42650)
Important
Please, check "Annual Orphan Drugs Congress" official website for possible changes, before making any traveling arrangements
